Farhad Hafezi, MD, PhD
Show Description +
In addition to its use in halting the progression of keratoconus, CXL also has the potential to treat corneal infections, Farhad Hafezi, MD, PhD, says. Accelerated CXL for treatment of infectious keratitis is currently undergoing phase 2 and 3 clinical trials in 10 countries. Professor Hafezi says he is hopeful that someday photoactivated chromophore for keratitis CXL, or PACK-CXL, will not only be an adjuvant to antibiotics but a first-line treatment for early ulcers.
Posted: 4/28/2017
Farhad Hafezi, MD, PhD
In addition to its use in halting the progression of keratoconus, CXL also has the potential to treat corneal infections, Farhad Hafezi, MD, PhD, says. Accelerated CXL for treatment of infectious keratitis is currently undergoing phase 2 and 3 clinical trials in 10 countries. Professor Hafezi says he is hopeful that someday photoactivated chromophore for keratitis CXL, or PACK-CXL, will not only be an adjuvant to antibiotics but a first-line treatment for early ulcers.
Posted: 4/28/2017
Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of ASCRS: 2017.
Please log in to leave a comment.